Etoposide
. Draft fact sheet, awaiting Henry's approval. Items marked [check] must be verified before publishing.
← All drugs · Search the portal
Facts
| Topic | Fact | Source (access date) |
|---|---|---|
| First US approval record | VePesid (NDA 018768) original approval 10 Nov 1983, about 43 years | Drugs@FDA via openFDA, https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA018768 (accessed 4 Nov 2026) |
| Mechanism | Topoisomerase II inhibitor; semi-synthetic derivative of podophyllotoxin | openFDA label API, https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22ETOPOPHOS%22 (accessed 4 Nov 2026); eMC SmPC https://www.medicines.org.uk/emc/product/10514/smpc (accessed 4 Nov 2026) |
| Use in osteosarcoma | With ifosfamide at relapse or poor response; in French M-EI first line for young people; MAPIE in EURAMOS-1 | UK bone sarcoma guidelines 2024, https://pmc.ncbi.nlm.nih.gov/articles/PMC11723950/ (accessed 3 Nov 2026); treatment_by_country.md |
| Combined with | Ifosfamide; MAP (MAPIE); methotrexate and ifosfamide (M-EI) | EURAMOS-1 MAPIE vs MAP, Marina et al., Lancet Oncol 2016, doi:10.1016/S1470-2045(16)30214-5 (PMID 27569442), accessed 3 Nov 2026 |
| Results | EURAMOS-1 MAPIE: no event-free survival benefit (HR 0.98) | EURAMOS-1 MAPIE vs MAP, Marina et al., Lancet Oncol 2016, doi:10.1016/S1470-2045(16)30214-5 (PMID 27569442), accessed 3 Nov 2026 |
| Side effects | Low blood counts (dose-limiting), hair loss, nausea and vomiting; secondary acute leukaemia reported | eMC SmPC https://www.medicines.org.uk/emc/product/10514/smpc (accessed 4 Nov 2026); openFDA etoposide label (accessed 4 Nov 2026) |
| Owner and generic status | US VePesid (Bristol-Myers) 1983; now generic; current US NDA holder Corden Pharma | Drugs@FDA via openFDA, https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA018768 (accessed 4 Nov 2026) |
| Regulatory | UK: Etopophos (Neon Healthcare, PL 45043/0038, first 23 May 1996). EU (Ireland): Accord PA2315/201/001, testicular, small cell lung, Hodgkin lymphoma and others; osteosarcoma not named. US: testicular, small cell lung. China: domestic approvals e.g. H20263245 (2026). Not licensed for osteosarcoma | eMC SmPC https://www.medicines.org.uk/emc/product/10514/smpc (accessed 4 Nov 2026); HPRA SmPC https://assets.hpra.ie/products/Human/27660/Licence_PA2315-201-001_13032024133422.pdf (accessed 4 Nov 2026); NMPA approval number H20263245 via yaopinnet.com mirror, https://www.yaopinnet.com/H/H45/H20263245.htm (accessed 4 Nov 2026); official NMPA register (datasearch.nmpa.gov.cn) returned HTTP 412 to automated access |